Omapatrilat

Drug Profile

Omapatrilat

Alternative Names: BMS 186716; BMS 186716-01; Vanlev

Latest Information Update: 10 Jan 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antihypertensives; Pyridines; Small molecules; Thiazepines
  • Mechanism of Action ACE inhibitors; Endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Angina pectoris; Heart failure; Hypertension; Myocardial infarction

Most Recent Events

  • 26 May 2003 Data presented at the 18th Annual meeting of the American Society of Hypertention (ASH-2003) have been added to the Hypertension pharmacodynamics section
  • 15 Oct 2002 The FDA have issued Bristol-Myers Squibb with an action letter regarding approval of Vanlev®
  • 24 Sep 2002 A study has been added to the adverse events and Heart Failure therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top